Discontinuation of dimethyl fumarate in multiple sclerosis - a nationwide study

Risk factors for development of lymphopenia in dimethyl fumarate-treated patients with multiple sclerosis

(2022) Julie Ravn et al.   Multiple Sclerosis and Related Disorders

Tolerability and safety of dimethyl fumarate in relapsing multiple sclerosis: a prospective observational multicenter study in a real-life Spanish population

(2020) Julia Sabin et al.   JOURNAL OF NEUROLOGY

Nursing Management of Gastrointestinal Adverse Events Associated With Delayed-Release Dimethyl Fumarate

(2020) Trudy L. Campbell et al.   JOURNAL OF NEUROSCIENCE NURSING

Medication adherence/persistence among patients with active multiple sclerosis in Finland

(2020) Sanni Lahdenperä et al.   ACTA NEUROLOGICA SCANDINAVICA

Comparative effectiveness of teriflunomide vs dimethyl fumarate in multiple sclerosis

(2019) David-Axel Laplaud et al.   NEUROLOGY

Safety and Efficacy of Dimethyl Fumarate in Multiple Sclerosis: An Italian, Multicenter, Real-World Study

(2018) Massimiliano Mirabella et al.   CNS DRUGS

Early versus later treatment start in multiple sclerosis: a register-based cohort study

(2018) T. A. Chalmer et al.   EUROPEAN JOURNAL OF NEUROLOGY

Two-year real-life efficacy, tolerability and safety of dimethyl fumarate in an Italian multicentre study

(2018) Giulia Mallucci et al.   JOURNAL OF NEUROLOGY

Real-life persistence and tolerability with dimethyl fumarate

(2018) Tobias Sejbaek et al.   Multiple Sclerosis and Related Disorders

Persistence with dimethyl fumarate in relapsing-remitting multiple sclerosis: a population-based cohort study

(2017) Irene Eriksson et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Excess mortality among patients with multiple sclerosis in Denmark has dropped significantly over the past six decades: a population based study

(2017) Nils Koch-Henriksen et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

The impact of persistence with therapy on inpatient admissions and emergency room visits in the US among patients with multiple sclerosis

(2016) Nina Parikh Thomas et al.   JOURNAL OF MEDICAL ECONOMICS

Efficacy and tolerability of dimethyl fumarate in White-, African- and Hispanic- Americans with multiple sclerosis

(2016) Lana Zhovtis Ryerson et al.   Therapeutic Advances in Neurological Disorders

Narrative Review of the Literature on Adherence to Disease-Modifying Therapies Among Patients with Multiple Sclerosis

(2016) Joseph Menzin et al.   JOURNAL OF MANAGED CARE PHARMACY

Comparative analysis of first-year fingolimod and natalizumab drug discontinuation among Swedish patients with multiple sclerosis

(2015) T Frisell et al.   Multiple Sclerosis Journal

Comparative analysis of first-year fingolimod and natalizumab drug discontinuation among Swedish patients with multiple sclerosis

(2015) T Frisell et al.   Multiple Sclerosis Journal

The Prevalence, Impact, and Treatment of Migraine and Severe Headaches in the United States: A Review of Statistics From National Surveillance Studies

(2013) Todd A. Smitherman et al.   HEADACHE

Impact of adherence to disease-modifying therapies on clinical and economic outcomes among patients with multiple sclerosis

(2010) Hiangkiat Tan et al.   ADVANCES IN THERAPY

Impact of Adherence to Interferons in the Treatment of Multiple Sclerosis

(2010) Stephanie C. Steinberg et al.   CLINICAL DRUG INVESTIGATION